Identifying the genes responsible for causing breast cancer and developing newer molecular treatments are among key areas of focus for researchers at the National Breast Cancer Research Institute (NBCRI).

The charity this week launched its first three-year strategic plan at its base in the Lambe Institute at the University of Galway where chairperson Caroline Loughnane outlined the current cancer research programme.

Researchers are working on the biomarkers of response to treatment and examining newer therapies targeted to individual patients. Some are investigating the role of stem cells in breast reconstruction.

As well as contributing to major international partnerships on cancer genetics and medical devices development, staff are also running clinical trials on newer treatments, all with the aim of improving treatments and outcomes for patients.

Research conducted at the Newcastle campus such as the study of microRNAs in breast cancer and the role played by mesenchymal stem cells in tumour was having an impact nationally as well as globally, she explained.

“This research spans the continuum from bench to bedside with the aim of improving treatments and outcomes for patients,” she stated.

The board of the charity has adopted six main goals under its new strategic plan. These will be monitored every three months to ensure they are progressed.

Get the full story in this week’s Connacht Tribune, on sale in shops now, or you can download the digital edition from www.connachttribune.ie. You can also download our Connacht Tribune App from Apple’s App Store or get the Android Version from Google Play.